局部卡尔西波特里奥尔加伊米基莫德免疫疗法用于非角质细胞皮肤癌
Marjan Azin1,2, Kenneth H Ngo1,2, Jennet Hojanazarova1,2
1Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
局部使用的calcipotriol和imiquimod协同作用,增强T细胞对皮肤癌的免疫力. 这种组合疗法增强了适应性免疫力,改善了乳腺癌转移和黑色素瘤的治疗结果.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 在瘤学瘤学.
背景情况:
- 乳腺癌转移和黑色素瘤等非皮细胞皮肤恶性瘤的手术治疗具有挑战性.
- 伊米基莫德 (IMQ) 是一种先天性免疫激活剂,由于适应性免疫激活适度有限,其作为单一疗法的疗效有限.
研究的目的:
- 为了研究局部胸膜 stromal lymphopoietin (TSLP) 细胞因子诱导剂与IMQ的协同作用,用于治疗非皮细胞皮肤恶性瘤.
- 评估这种组合疗法在增强CD4+T细胞免疫力和改善治疗结果方面的潜力.
主要方法:
- 利用局部皮醇和视网酸作为TSLP诱导剂与IMQ结合使用.
- 在乳腺癌和黑色素瘤模型中评估了瘤生长的减少.
- 在瘤微环境中分析了CD4+效应T细胞透.
- 研究了免疫检查点阻塞与免疫冷瘤联合治疗的疗效.
主要成果:
- 与单独治疗相比,局部西醇加IMQ显著降低了乳腺瘤的生长.
- 瘤抑制与增加CD4+效应T细胞透率有关.
- 组合疗法使免疫检查点封锁能够控制冷乳腺瘤.
- 局部用卡尔西波特醇/网红酸加IMQ抑制了皮下黑色素瘤的生长.
结论:
- 局部TSLP诱导剂与IMQ协同作用,激活CD4+T细胞免疫力对皮肤恶性瘤.
- 这种组合代表了对非角质细胞皮肤瘤的有希望的免疫疗法策略.
- 这些发现支持使用TSLP诱导与先天性免疫激活相结合,用于有效的皮肤癌免疫疗法.
更多相关视频
09:37Combining Reflectance Confocal Microscopy with Optical Coherence Tomography for Noninvasive Diagnosis of Skin Cancers via Image Acquisition
Published on: August 18, 2022
09:42Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research
Published on: April 19, 2017
相关概念视频
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Clinical Applications of Epidermal Stem Cells
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
